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Abstract
Objective: The objective of this study was to present the treatment technique and evaluate clinical
outcomes after intensity modulated radiation therapy (IMRT) for vulvar cancer.
Methods and materials: This retrospective study included 39 patients with squamous cell carci-
noma of the vulva treated with IMRT from 2005 to 2015. There were 21 patients treated with
postoperative IMRT, 13 with deﬁnitive IMRT, and 5 with preoperative IMRT. Tumor staging was
Federation of Gynecology and Obstetrics stage I in 6, stage II in 7, stage III in 19, and stage IV in 7
patients. Concurrent chemotherapy was administered to 14 patients. Brachytherapy was delivered
in 8 patients.
Results: The median follow-up was 34 months (range, 3.3-71). Median IMRT dose to patients
receiving pre- or postoperative IMRT was 5040 cGy (range, 5040-6080). Median combined IMRT
and brachytherapy dose to gross tumor was 7000 cGy (range, 5040-7520) in those treated with
deﬁnitive RT. The 3-year locoregional control (LRC) and overall survival for those receiving
postoperative RT were 89% and 67%, respectively. The 3-year LRC and overall survival for those
receiving deﬁnitive IMRT were 42% and 49%, respectively. In patients receiving deﬁnitive or
neoadjuvant IMRT, 69% had complete clinical response and 44% had complete pathologic response.
The actuarial 3-year inguinal recurrence rate was 7%. There were no acute grade 3-4 hematological,
gastrointestinal, or genitourinary toxicities. There were no late grade 3-4 gastrointestinal or
genitourinary toxicities.
Conclusions: IMRT for vulvar cancer is associated with high rates of LRC in the postoperative
setting and limited radiation-related toxicity. Durable LRC of disease after deﬁnitive IMRT
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remains challenging, and several reﬁnements to our treatment technique are suggested.
ª 2017 the Authors. Published by Elsevier Inc. on behalf of the American Society for Radiation
Oncology. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Radiation therapy (RT) has played an important role in
the treatment of vulvar cancer in both the pre- and
postoperative settings and the deﬁnitive setting.1,2 Radia-
tion has traditionally been administered in the supine,
frog-legged position using opposed anteroposterior-
posteroanterior ﬁeld setup in addition to supplemental
dose to the vulva or inguinal nodes as needed. Beriwal et al3
and Bloemers et al4 have shown in dosimetric studies that
intensity modulated RT (IMRT) may be advantageous in
the treatment of vulvar cancer because it may reduce dose
to small bowel, rectum, bladder, and femurs.
The beneﬁt of IMRT in reducing toxicity in pelvic
malignancies has been demonstrated in multiple prospec-
tive phase 2 trials.5,6 Additionally, phase 3 randomized
trials comparing postoperative 3-dimensional conformal
RT (3D-CRT) versus IMRT have been performed for
cervical cancer in India7 and for cervical or endometrial
cancer in a multinational setting.8 Preliminary data from
these studies also suggest reduced acute or late toxicity
with IMRT. IMRTmay reduce dose to pelvic bones, which
could in turn reduce hematologic toxicity for patients
receiving concurrent chemotherapy.6 Beriwal et al have
published extensively on the use of preoperative IMRT
with concurrent chemotherapy for vulvar cancer, which
resulted in a complete pathologic response rate (pCR) of
48.5% and limited treated-related toxicity.3,9,10 There is
additional interest in the use of IMRT for vulva cancer after
the publication of consensus contouring guidelines11 and
National Comprehensive Cancer Network12 clinical
guidelines allowing IMRT as a therapeutic option. The
Gynecological Oncology Group (GOG) has opened a
clinical trial (protocol 279) that prospectively investigates
combined weekly gemcitabine and cisplatin chemotherapy
with IMRT to 6400 cGy in patients with locally advanced
vulvar cancer.13 The purpose of our study was to present
our institutional experience of IMRT in the treatment of
vulvar cancer with an emphasis on treatment technique,
patient outcomes, and toxicity.
Methods and materials
Study population
The records of 39 patients with squamous cell carcinoma
of the vulva treated with curative intent IMRT at
Washington University in St. Louis School of Medicine
from January 2005 to January 2015 were reviewed. All
patients underwent a complete staging workup according to
the International Federation of Gynecology and Obstetrics
2009 edition and American Joint Committee on Cancer, 7th
edition, clinical staging criteria, including a full history and
physical examination, routine laboratory evaluation, and
metastatic evaluation. Patients underwent imaging with 18-
ﬂuoro-deoxyglucose positron emission tomography (FDG-
PET) (33 of 39), magnetic resonance imaging (10 of 39),
and/or computed tomography (CT) (39 of 39). The data
source for this study was the Washington University in St.
Louis radiation oncology department’s institutional review
boardeapproved, retrospective registry of treatment data
(institutional review board approval #20131149). The data
were deidentiﬁed by an “honest broker” before research use.
Surgical resection
Surgical resection was performed in 26 patients, whereas
13 had a biopsy alone. A radical vulvectomywas performed
in 16 patients, and 10 had a modiﬁed radical vulvectomy,
hemivulvectomy, or wide local excision. Bilateral inguinal
lymph node dissection was performed in 19 patients.
Sentinel lymph node sampling was performed in 2 patients.
Radiation
All patients received IMRT with or without high-dose-
rate (HDR) brachytherapy. Adjuvant postoperative IMRT
was administered to patients with high-risk features such
as surgical margins <8 to 10 mm, extracapsular exten-
sion, >1 positive lymph node, or lymphovascular space
invasion.14 Deﬁnitive or neoadjuvant IMRT was per-
formed for unresectable tumors, medically inoperable
patients, or patients in which surgical resection had a high
likelihood of unacceptable gastrointestinal (GI) or geni-
tourinary (GU) toxicity. All patients underwent a treat-
ment planning CT simulation for IMRT. Patients
receiving deﬁnitive or neoadjuvant IMRT underwent
FDG-PET/CT simulation. Diagnostic FDG-PET scans
were fused with the planning CT to aid in treatment
planning. Patients were routinely simulated in the supine
position with the legs straight and were ﬁtted with a
customized immobilization device (Alpha Cradle,
Smithers Medical Products, Inc, North Canton, OH) to
minimize daily setup variability. Bolus on the vulva was
not routinely used in the postoperative setting, but was
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used over the vulvar tumor and superﬁcial or bulky lymph
nodes in the deﬁnitive or preoperative setting. Treatment
positioning was conﬁrmed via daily 2-dimensional
imaging as well as weekly cone beam CT.
IMRT planning
The gross tumor volume (GTV) as deﬁned by FDG-PET
and the clinical target volume (CTV), and organs at risk
were contoured for treatment planning. The entire vulva
was included in the vulvar CTV (CTVvulvar). The low
pelvic vessels were contoured from 1 cm above the bifur-
cation of the common iliac artery and extended inferiorly to
include the internal and external iliac vessels, the obturator
space, and the inguinal region along the femoral vessels
until the deep femoral artery branches and goes deep into
the thigh. An isotropic 7-mm expansion was performed on
the vessel contour, excluding the pelvic bones, to create the
nodal CTV (CTVnodal). Of note, more recent consensus
guidelines recommend contouring the CTVnodal in the
inguinal region as a compartment rather than as a 7-mm
isotropic expansion on the inguinal vessels; this will be
discussed in detail later. TheCTVnodal was edited to include
FDG-avid or involved lymph nodes. The CTVvulvar and
CTVnodal were combined to form the ﬁnal CTV (CTVﬁnal)
as seen in Fig 1. The planning target volume was deﬁned as
a 5-mm isotropic expansion on the CTVﬁnal.
The IMRT prescription doses to the CTVﬁnal ranged
from 5040 to 5120 cGy in 160 to 180 cGy per fraction. The
GTV was typically treated to a total dose of 6000 to 7000
cGy via an integrated boost in 200 cGy per fraction. Some
patients received a lower dose of 5040 cGy to the vulva
GTV by IMRT; and additional dose was given later
by brachytherapy to achieve a total dose of >6000 cGy.
FDG-avid nodal disease typically received an integrated
boost of 6000 to 6600 cGy in 180 to 200 cGy per fraction.
The median doses and ranges for adjuvant and neoadjuvant
IMRT were 5040 cGy (range, 4960-6080 cGy) and 5040
cGy (range, 5040-6000 cGy), respectively. In patients
treated deﬁnitively, the median external beam dose to the
vulva (not including dose from brachytherapy) was 6000
cGy (range, 5040-7000 cGy) and the median total deﬁni-
tive dose to the vulva including brachytherapy (8 patients
with IMRT and brachytherapy; 5 patients with IMRT
alone) was 7000 cGy (range, 5040-7520 cGy). The median
IMRT dose to the involved FDG-avid lymph nodes was
6000 cGy (range, 5040-7000 cGy). Plans were created to
limit the percentage of rectum receiving doses >40 Gy
(V40) to<60%, bladder V45 Gy to<50%, bowel V40 Gy
to <30%, unilateral kidney to <20 Gy, and spinal cord
maximum dose to <45 Gy.
Brachytherapy
HDR iridium-192 interstitial brachytherapy was per-
formed in 8 patients. We typically select patients with
locally advanced disease, large tumor at diagnosis, or re-
sidual vulva disease after IMRT for brachytherapy
consolidation. We intended to delivery brachytherapy to
most patients treated with deﬁnitive IMRT because they
typically fall within these criteria. Of the 5 patients treated
with deﬁnitive IMRT who did not receive brachytherapy,
the reasons for not performing brachytherapy consolida-
tion included identiﬁcation of distant progression before
implant, death before completion of IMRT, declining
performance status, patient noncompliance, and
Figure 1 Representative axial slices of vessel, nodal clinical target volume (CTV), and vulva CTV contours. Top left: inferior extent of
vessel contour and vulva CTV contour. Top right: level of the partial vulvectomy site (marked by ﬁducial) and ischial ramus. Bottom left:
level of the pubic symphysis. Bottom right: level of the femoral heads. Blue, vessel contour; green, vulva CTV; red, nodal CTV.
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brachytherapy not indicated because of small tumor at
initial diagnosis and complete response by IMRT.We used
the brachytherapy method described by Dyk et al15 and
placed interstitial catheters in the region of the vulvar tumor
with the aid of a template. CT simulation was used in
treatment planning, and a brachytherapy treatment plan
with uniform loading was prescribed to cover the implant
volume. The median HDR brachytherapy dose was 1200
cGy (range, 1000-2000 cGy) in 8 fractions delivered twice
per day over a 4-day period. HDR brachytherapy was
performed 3 weeks after completion of IMRT. The median
combined dose to the vulva was 7120 cGy (range, 6240-
7520 cGy) in patients who completed deﬁnitive IMRT and
consolidative brachytherapy.
Chemotherapy
Concurrent chemotherapy was administered to 14
patients. The decision to include chemotherapy was made
by the treating physician based on patient-speciﬁc criteria
and was typically preferred for locally advanced disease.
Of the patients that received chemotherapy, 13 received
weekly cisplatin (40 mg/m2) while one patient received
cisplatin (100 mg/m2, day 1) and 5-ﬂuorouracil (1000 mg/
m2/day, days 1-5) every 3 weeks.
Toxicity evaluation
Patients were retrospectively scored for acute and late
toxicity using the Radiation Therapy Oncology Group
(RTOG) toxicity criteria.16 Acute toxicities were deﬁned as
events occurring <90 days after initiation of RT, whereas
late toxicities were deﬁned as events occurring 90 days
after the initiation of RT. Acute hematologic toxicities were
retrospectively scored for those receiving chemotherapy.
Follow-up and response assessment
The patients were seen at 6 weeks, 3 months, 6 months,
12 months, and at least annually after completion of RT.
Locoregional control (LRC) was deﬁned as time until
biopsy proven recurrence in the vulva or regional lymph
nodes, with censoring at last follow-up or death. Overall
survival (OS) was deﬁned as time until death with censoring
at last follow-up in patients still alive. Follow-up times used
in the LRC and OS analysis were deﬁned starting from the
date of diagnosis. The date of diagnosis rather than date of
completion of radiation was selected for the starting time to
allow for a uniform comparison of patients treated with
adjuvant, neoadjuvant, and deﬁnitive radiation. Complete
clinical response (cCR) was deﬁned as no evidence of
disease noted on physical examination after completion of
radiation. Complete pathological response (pCR) was
deﬁned as a biopsy or surgery of the vulva showing no
carcinoma within 1 year of completion of radiation.
Statistical analysis
The Kaplan-Meier method was used to derive estimates
of LRC andOS. The log-rank test and univariate analysis of
Cox proportional hazards models were used to evaluate the
impact of clinical factors and patient characteristics on LRC
and OS. Multivariate analysis was not performed because
of the relatively small number of patients. Patterns of
recurrence and toxicity proﬁles were compared using thec2
test or Fisher exact test, as appropriate. Statistical signiﬁ-
cance was considered as a P < .05. All levels of signiﬁ-
cance were 2-sided. Numerical P values are reported in
tables if <.10 and marked as not signiﬁcant if .10.
Results
Patient characteristics
The median follow-up was 34 months (range, 3.3-71).
Median age was 62 years (range, 27-93). International
Federation of Gynecology andObstetrics stage at diagnosis
was stage I in 6 (15%), stage II in 7 (18%), stage III in
19 (49%), and stage IV in 7 (18%) patients. None had
distant metastatic disease at diagnosis. IMRT to the vulva,
pelvic lymph nodes, and inguinal lymph nodes was deliv-
ered to 35 (87%) patients and vulva-only IMRT was
delivered to 4 (13%) patients. The median total duration of
IMRT was 41 days. Two patients (5%) had prolonged
duration of IMRT of 50 days; both of these patients later
developed locoregional recurrence. Additional clinical and
pathologic characteristics are summarized in Table 1.
LRC after postoperative IMRT
Twenty-one patients received postoperative IMRT.
Locoregional recurrence occurred in 3 patients; of these,
2 were in the vulva and 1 was in an inguinal node. The
median time to locoregional recurrence was 12 months
(range, 7.5-38). The 3-year actuarial LRC rate was 89% for
those receiving postoperative IMRT as shown in Fig 2. The
crude rates of vulvar and inguinal recurrence were 10% (2
of 21) and 5% (1 of 21), and the 3-year actuarial rates of
vulvar and inguinal recurrence were 5% and 6%, respec-
tively. Of the 2 patients with vulva recurrence, the dose to
the vulva was 5940 cGy in a patient with a positive surgical
margin and 5120 cGy in a patient with a widely negative
margin. The inguinal nodal recurrence occurred at a site of a
previously resected 3-cm lymph node with extracapsular
extension; the inguinal radiation dose was 5040 cGy. On
Cox univariate analyses, surgical resection of the primary
vulvar tumor (hazard ratio [HR], 0.27; 95% conﬁdence
interval [CI], 0.07-0.99, P Z .05) was associated with
improved LRC and tumor size >3 cm (HR, 5.84; 95% CI,
1.09-31.41; PZ .04) were associated with worse LRC, as
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Table 1 Demographics and univariate analysis of LR control
All patients LR recurrence LRC Cox univariate
HR (95% CI)
P
n % (total) n % (row)
Age
<70 y 28 72 6 21 Reference
70 y 11 28 3 27 2.16 (0.53-8.77) NS
Grade
NA 3
1 4 11 1 25 Reference
2 27 75 6 22 1.11 (0.13-9.43) NS
3 5 14 1 20 0.78 (0.05-13.08) NS
FIGO stage
I 6 15 0 0 No events
II 7 18 2 29 1.30 (0.12-14.43) NS
III 19 49 6 32 1.74 (0.21-14.46) NS
IV 7 18 1 14 Reference
AJCC stage
T1-T2 N0 13 33 2 15 Reference
T3 N0 4 10 0 0 No events
T1-3 N1 10 26 2 20 1.22 (0.17-8.88) NS
T1-3 N2 11 28 5 46 4.48 (0.82-24.47) NS
T1-3 N3 or pelvic LNþ 1 3 0 0 No events
Nodal status
Negative 17 44 2 12 Reference
Positive 22 56 7 32 3.20 (0.66-15.47) NS
Treatment strategy
Deﬁnitive radiation 13 33 5 39 Reference
Adjuvant radiation 21 54 3 14 0.24 (0.06-0.99) 0.05
Neoadjuvant radiation 5 13 1 20 0.41 (0.05-3.60) NS
Surgical resection
No 13 33 5 39 Reference
Yes 26 67 4 15 0.27 (0.07-0.99) 0.05
Type of vulva surgery
Biopsy only 13 33 5 39 Reference
WLE/HV/MRV 10 26 1 10 0.19 (0.02-1.63) NS
Radical vulvectomy 16 41 3 19 0.31 (0.07-1.29) NS
Radiation volume
Vulva only 4 13 0 0 No events
Vulva, pelvis, inguinal 35 87 9 26 NS
Radiation dose, Gy
51.2 28 72 6 21 Reference
>51.2 11 28 3 27 1.32 (0.33-5.30) NS
Brachytherapy
No 31 80 7 23 Reference
Yes 8 20 2 25 0.74 (0.15-3.61) NS
Concurrent chemotherapy
No 25 64 6 24 Reference
Yes 14 36 3 21 0.96 (0.24-3.85) NS
Tumor size
NA 8
3 cm 18 58 2 11 Reference
>3 cm 13 49 5 39 5.84 (1.09-31.41) 0.04
Surgical margin
NA 15
8 mm 8 33 2 25 Reference
<8 mm 10 42 1 10 0.54 (0.05-5.94) NS
Positive 6 25 1 17 0.58 (0.05-6.38) NS
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seen in Table 1. Additional information on patterns of
recurrence is in Table 2.
LRC after deﬁnitive IMRT
Thirteen patients received deﬁnitive IMRT. Locoregional
recurrence occurred in 5 patients receiving deﬁnitive IMRT;
of these, 4 were in the vulva and 1 was in an inguinal lymph
node. The median time to locoregional recurrence was
9 months (range, 3.2-25). The 3-year actuarial LRC rate after
deﬁnitive IMRTwas 42%, as shown in Fig 2. The crude rates
of vulvar and inguinal recurrence were 31% (4 of 13) and 8%
(1 of 13), and the 3-year actuarial rates of vulvar and inguinal
recurrence were 53% and 12%, respectively. The actuarial
rates are higher than the crude rates because of patients lost to
follow-up or death from metastatic disease or other causes
before 3 years. Two of the patients who developed recurrent
Table 1 (continued )
All patients LR recurrence LRC Cox univariate
HR (95% CI)
P
n % (total) n % (row)
Depth of invasion
NA 21
9 mm 13 72 3 23 Reference
>9 mm 5 28 1 20 1.07 (0.11-10.58) NS
Lymphovascular invasion
NA 16
Negative 12 52 3 25 Reference
Positive 11 48 2 18 0.93 (0.15-5.56) NS
LR, locoregional; LVSI, lymphovascular space invasion; NA, unknown or not applicable; NS, not statistically signiﬁcant; WLE/HV/MRV, wide local
excision/hemivulvectomy/modiﬁed radical vulvectomy.
P-values in bold indicate statistically signiﬁcant associations.
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Figure 2 Kaplan-Meier curves for locoregional control and overall survival by tumor stage, tumor size, and treatment strategy.
(A) Locoregional control by American Joint Committee on Cancer stage. (B) Locoregional control by tumor size. (C) Locoregional
control by treatment strategy. (D) Overall survival by treatment strategy. RT, radiation therapy.
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vulvar disease initially received 5040 cGy by IMRT and no
consolidation because of noncompliance in 1 patient and
decline in performance status as well as local progression of
tumor, making it not amenable to consolidative brachyther-
apy or surgery, in another patient. The other 2 patients with
vulvar recurrence initially received 6600 cGy by IMRT for an
8-cm vulvar tumor or 5040 cGy by IMRT followed by 2000
cGy brachytherapy for a 6-cm vulvar tumor. The inguinal
nodal recurrence occurred within a 4-cm FDG-avid lymph
node that was treated to 6000 cGy.
Brachytherapy was delivered after IMRT in 8 patients.
The cumulative dose was 5040 cGy by IMRT plus a median
of 2000 cGy (range, 1200-2000 cGy) by brachytherapy in
3 patients and6000cGyby IMRTplus amedianof 1200cGy
(range, 1000-1520 cGy) by brachytherapy in 5 patients.
Among the patientswho completed deﬁnitive treatmentwith
IMRTand brachytherapy, therewas 1 vulvar recurrence, and
the crude and actuarial 3-year vulvar recurrence rates were
13% and 15%, respectively. None of the 5 patients who
successfully completed deﬁnitive treatment of 6000 cGy by
IMRT followed by brachytherapy consolidation to a total
dose of 7000 cGy or higher developed vulvar recurrence at a
median follow-up of 25 months (range, 8.5-60).
LRC after neoadjuvant IMRT
Five patients were treated with neoadjuvant IMRT.
One vulvar recurrence occurred, and the crude and 3-year
actuarial LRC rates in this group were both 80%. This
patient was initially treated to a dose of 5040 cGy
followed by radical vulvectomy, which showed residual
tumor in the vulva and inguinal nodes in the pathology
specimen. This patient developed a vulvar recurrence 10
months after treatment.
Treatment response
Clinical response and pathologic response could be
assessed from available reports in 16 (89%) and 13 (72%)
patients, respectively, of the 18 patients who received
neoadjuvant or deﬁnitive IMRT. cCRwas observed in 61%
(11 of 18) of the patients overall and 69% (11 of 16) when
adjusted for the number of evaluable patients. pCR was
observed in 44% (8 of 18) of patients overall and 62% (8 of
13) when adjusted for the number of evaluable patients.
Concurrent chemotherapy with IMRT yielded a 78% (7 of
9) rate of cCR compared with 57% (5 of 7) for IMRT alone
in evaluable patients. Concurrent chemotherapy yielded a
67% (4 of 6) rate of pCR compared with 57% (4 of 7) for
IMRT alone in evaluable patients. The use of concurrent
chemotherapy was not statistically signiﬁcant for increased
odds of cCR (PZ .38) or pCR (PZ .73) as assessed by
logistic regression compared with patients treated with
IMRT alone. cCR and pCR were not signiﬁcantly associ-
ated with improved LRC (P Z .50 and P Z .43, respec-
tively) or OS (P Z .37 and P Z .44, respectively), as
Table 2 Patterns of recurrence
No recurrence Vulva Inguinal Distant
n % (row) n % (row) n % (row) n % (row)
All patients 27 69 7 18 2 5 3 8
FIGO stage
I 6 100 0 0 0 0 0 0
II 5 71 2 29 0 0 0 0
III 11 58 4 21 2 11 2 11
IV 5 71 1 14 0 0 1 14
AJCC stage
T1-T2 N0 11 85 2 15 0 0 0 0
T3 N0 4 100 0 0 0 0 0 0
T1-3 N1 6 60 2 20 0 0 1 10
T1-3 N2 6 55 3 27 2 18 1 9
T1-3 N3 or pelvic LNþ 0 0 0 0 0 0 1 100
Treatment strategy
Deﬁnitive radiation 7 54 4 31 1 8 2 15
Adjuvant radiation 16 76 2 10 1 5 1 5
Neoadjuvant radiation 4 80 1 20 0 0 0 0
Brachytherapy
No 21 68 6 19 1 3 3 10
Yes 6 75 1 13 1 13 0 0
Concurrent chemotherapy
No 17 68 4 16 2 8 1 4
Yes 10 71 3 21 0 0 2 14
FIGO, International Federation of Gynecology and Obstetrics; RTOG, Radiation Therapy Oncology Group.
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assessed by univariate Cox regression. Five patients could
not be evaluated for pathologic response: 1 patient died of
sepsis related to chemoradiation and another died of
unrelated end-stage renal disease in the follow-up period.
The remaining 3 patients who could not be assessed for
pCR had cCR but did not receive vulvar biopsy or surgery
within 1 year. One of these patients developed vulvar
recurrence after 1 year, 1 developed distant metastatic
disease, and the ﬁnal patient was free from recurrence at 14
months of follow-up.
Overall survival
At the time of last follow-up, 5 patients had died of
disease and 3 patients had died of intercurrent disease.
The actuarial OS rates of the entire cohort were 82%,
72%, and 68% at 1, 2, and 3 years, respectively. The
3-year actuarial OS rate was 67% for those receiving
postoperative irradiation, 49% for those receiving irradi-
ation alone, and 100% for those receiving preoperative
irradiation, as shown in Fig 2. On univariate analysis, age
>70 years was associated with worse OS (HR, 5.15; 95%
CI, 1.62-16.36; P < .01). Development of distant meta-
static disease was associated with worse OS (HR, 15.42;
95% CI, 3.04-78.27; P Z .01), but locoregional recur-
rence was not signiﬁcantly correlated with OS (PZ .26).
Distant metastasis
At last follow-up, 3 (8%) patients developed distant
metastasis, with 2 occurring in patients treated with
deﬁnitive radiation and 1 in a patient treated with adjuvant
radiation. Median time to distant recurrence was 6 months
(range, 3.2-7.2 months). One patient had metastatic
disease to the lung, 1 to the liver, and 1 had widespread
disease, including the liver, lung, and bone. No clinical
variables were associated with distant metastatic disease
on univariate analysis.
Toxicity
Treatment-related toxicities are shown in Table 3.
Grade 2 or greater acute dermatologic toxicity was seen in
36 (92%) patients. No patients developed acute or late
grade 3-4 GI or GU toxicities. All acute and late GI
toxicity and lymphangitis occurred in patients receiving
IMRT to both the vulva and regional lymph nodes. Of the
14 patients who received concurrent chemotherapy, 5
(36%) developed acute grade 2 leukopenia and 3 (21%)
developed acute grade 2 anemia. There were no acute
grade 3-4 hematologic toxicities. In regard to late skin
toxicity, 2 (5%) patients developed lymphangitis, and no
patients had vulvar necrosis or nonhealing ulceration. One
death occurred while a patient was receiving deﬁnitive
chemoradiation therapy for a cT3N2M0, 9-cm vulvar
squamous cell carcinoma with rectal and anal involve-
ment. Weekly concurrent cisplatin and daily IMRT was
stopped at 4800 cGy (planned, 6080 cGy) after the patient
developed a rectovaginal ﬁstula. She received a diverting
colostomy 3 days after her last IMRT fraction. Unfortu-
nately, she developed sepsis and died postoperatively.
Discussion
In our study, surgical resection of the primary vulvar
tumor was associated with improved LRC. Postoperative
radiation may also improve LRC by treating residual or
microscopic disease in patients with high-risk features as
deﬁned by Heaps et al,14 or with close or positive margins.17
Dusenbery et al reported that full-dose radiation to the vulva
was necessary in patients with locally advanced disease, even
after radical vulvectomy.18 Additionally, Viswanathan et al
reported that adjuvant RT doses>5600 cGy were associated
with improved LRC, especially in the setting of close or
positive margins.19 Furthermore, a review of the National
Cancer Database suggests that patients with node-positive
vulvar cancer after surgery may beneﬁt from chemotherapy
in addition to adjuvant radiation20 and that the optimal
postoperative radiation dose for margin positive vulvar can-
cer is likely in the range of 5400 to 6000 cGy.21 Data in the
literature are limited on the use of IMRT in the adjuvant
setting, and previous studies of adjuvant 3D-CRT reported
LRC rates of 67% to 82%.17-19 In our study, we observed a
3-year LRC of 89% in patients treated with adjuvant IMRT,
suggesting that the increased conformality of adjuvant IMRT
does not compromise LRC in the adjuvant setting.
Deﬁnitive or neoadjuvant chemoradiation are also
reasonable treatment strategies in patients who do not qualify
for primary surgery. The goal of radiation in this setting is to
induce a complete tumor response or to decrease the extent of
tumor to allow for resection. These strategies are supported
by a Cochran review that found no difference in survival
between primary chemoradiation and surgery.22 GOG 205, a
phase 2 trial of neoadjuvant 3D conformal chemoradiation
with weekly cisplatin, had a cCR rate of 64% and a pCR rate
of 50%.23 IMRT in the neoadjuvant setting has been exten-
sively investigated by Beriwal et al, who treated patients with
twice-daily IMRT to a median dose of 4640 cGy concurrent
with cisplatin/5-ﬂuorouracil.3,9,10 They observed a pCR rate
of 48.5%and 3-year recurrence free survival of 65.9%. These
promising results have led to an ongoing phase 2 trial, GOG
279,which is investigatingdeﬁnitive IMRT to 6400 cGywith
concurrent weekly gemcitabine and cisplatin. At our institu-
tion, in patients receiving deﬁnitive radiation, we delivered a
median total dose from IMRT plus brachytherapy of 7000
cGy to the vulvar tumor. In our series, these patients achieved
an unadjusted cCR rate of 61%and an unadjusted pCR rate of
44%,which are similar to the response rates of prior studies of
radiation with or without IMRT. Despite these favorable
initial response rates, LRC in patients treated with deﬁnitive
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radiation was unsatisfactory at 42% at 3 years. Surgery either
before or after radiation is associated with improved local
control in our study, and should be considered for patients
with vulvar cancer. For patients who cannot undergo surgery,
additional therapy such as concurrent chemotherapy, dose
escalation, and consolidative brachytherapy may be consid-
ered. Additional research is needed to determine patient se-
lection and evaluate the efﬁcacy of these treatment strategies.
In our series, some patients who later developed vulvar
recurrence after deﬁnitive radiation were treated with an
initial IMRT dose of 5040 cGy and planned for consoli-
dation by brachytherapy or surgery, but they later
received no further local therapy for various reasons, such
as noncompliance or early tumor progression. Patients
completing a course of deﬁnitive IMRT to a dose of 6000
cGy followed by brachytherapy did not develop vulvar
recurrence; therefore, in patients who are treated with
deﬁnitive or potentially preoperative radiation, an external
beam dose to the vulvar tumor GTV of less than 6000
cGy should be discouraged. Additional research investi-
gating brachytherapy consolidation in vulvar cancer is
warranted. We also observed that patients with a pro-
longed IMRT treatment time of >50 days also had a high
recurrence rate. Furthermore, quality control checks
should be considered for patients treated with deﬁnitive
IMRT to avoid the possibility of unintentionally under-
dosing the vulvar tumor. These checks could include
in vivo dose measurement using a thermoluminescent
dosimeter, veriﬁcation of the bolus positioning at the time
of the ﬁrst fraction, cone beam CT imaging, and moni-
toring for the necessity of treatment replanning because of
tumor shrinkage, vulvar edema, or other changes in
anatomy.
Appropriate radiation dose coverage of the inguinal
lymph nodes has long been a topic of interest in vulvar
cancer. GOG 88 demonstrated that a high rate of recur-
rence was attributed to underdosing of inguinal lymph
nodes.24,25 More recently, Glaser et al26 have expressed
concern regarding appropriate nodal coverage in modern
radiation protocols, especially after an interim analysis of
the Observation in Patients With Early-Stage Vulvar
Cancer Undergoing Sentinel Lymph Node Dissection
(GROINSS-V) II trial found an inguinal recurrence rate of
12.2%, a higher rate than expected.27 It is important to
note that GROINSS-V II used 3D-CRT planning and a
5-mm CTV margin around the femoral vessels; addi-
tionally, FDG-PET was not required as part of staging or
treatment planning. This differs from Kim et al’s analysis
that 2-cm margins around the femoral vessels are required
for coverage of potentially involved lymph nodes.28
Additionally, in the ongoing GOG 279 trial, the
inguinal region is deﬁned as a compartment similar to the
method described in the RTOG contouring guidelines for
anal cancer.29 Recently published vulvar cancer
consensus guidelines11 and National Comprehensive
Cancer Network guidelines12 also advocate contouring of
the inguinal nodes as a compartment.
We deﬁned the inguinal nodal CTV as a 7-mm expan-
sion of the femoral vessel contour; planning target volume
was an additional 5-mm expansion. These deﬁnitions have
historically been used at our institution but were smaller
than those advocated by recent guidelines11,12; however, as
described previously, these expansions were associated
with a 3-year recurrence rate of 7% in the inguinal nodes.
The actuarial rate of inguinal recurrence at 3 years was 6%
(crude rate of 5%, 1 of 21) in patients treated with post-
operative radiation and 12% (crude rate of 8%, 1 of 13) in
patients treated with deﬁnitive radiation. However, the
single nodal recurrence in the patient treated for deﬁnitive
radiation was within a previously involved node, and
therefore larger CTV expansions would not have inﬂu-
enced the outcome in this patient. A potential reason for our
recurrence rate may be the use of FDG-PET/CT in the
guidance of IMRT treatment volumes. A subset of patients
Table 3 Acute and late toxicity
Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
n % n % n % n % n % n %
Hematological
WBC 7 50 2 14 4 28 0 0 0 0 1 7
Platelets 12 86 2 14 0 0 0 0 0 0 0 0
Neutrophils 13 93 0 0 1 7 0 0 0 0 0 0
Hemoglobin 9 64 2 14 3 21 0 0 0 0 0 0
Acute skin 3 8 9 23 27 69 0 0 0 0 0 0
Acute GI 24 62 2 5 13 33 0 0 0 0 0 0
Acute GU 33 85 2 5 4 10 0 0 0 0 0 0
Late GI 37 95 2 5 0 0 0 0 0 0 0 0
Late GU 37 95 2 5 0 0 0 0 0 0 0 0
Fourteen patients treated with concurrent chemotherapy could be evaluated for hematological toxicity. Other toxicity could be evaluated in 39
patients. Percentages are of the total number of patients in the row of the table.
GI, gastrointestinal; GU, genitourinary; WBC, white blood cell.
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in the series by Beriwal et al had treatment planning with
FDG-PET/CT; the authors also reported a low rate of
inguinal recurrence of 0%.9 However, because our study
has a small number of patients with limited follow-up,
additional data are needed on whether treatment volumes
can be reduced with FDG-PET/CT imaging. We
acknowledge that the recently published consensus
guidelines, which recommend including the entire inguinal
compartment in the CTV, are the most conservative
approach to ensure coverage of the inguinal nodal region.11
The dose to the sites of inguinal recurrences in our study
were 5040 cGy in a patient with a resected 3-cm lymph
node with extracapsular extension and 6000 cGy in a pa-
tient with a previously unresected 4-cm lymph node. Dose
escalation by IMRT above these values for future patients
with extracapsular extension or unresected lymph nodes
may be considered. We present suggested doses to the
vulvar primary tumor, elective lymph nodes, and involved
lymph nodes (Table 4) based on our experiencewith IMRT,
as presented here, and taking into account data from other
published studies.
A goal of IMRT treatment is to reduce dose to organs
at risk and therefore decrease treatment-related toxicity.
The series by Beriwal et al reported no grade 3 chronic
GI or GU toxicity.9 We also observed no late grade 3 or
greater GI or GU toxicities. Additionally, in patients
receiving concurrent chemotherapy, we observed no
grade 3-4 hematological toxicity. Rates of grade 2
leukopenia and anemia were 36% and 21%, respectively,
which are comparable to the hematological toxicity rates
in a trial investigating IMRT for cervical cancer.6 It is
important to note, however, that 1 death from sepsis was
observed shortly after chemoradiation; therefore, caution
should be used when considering concurrent chemo-
radiation in elderly or frail patients.
A limitation of this study includes the relatively short
median follow-up time of 34 months, which precludes us
from evaluating long-term outcomes. Additionally, the
decision between treatment with deﬁnitive radiation,
adjuvant radiation, and neoadjuvant radiation was not
based on a randomization but on an individualized plan
using tumor and patient characteristics. As a result, a
comparison of the relative efﬁcacy of these strategies may
be confounded by selection bias. We allowed negative
biopsies to be included in our calculation of pCR, which
may be problematic because of sampling error. Our
observed toxicities post-IMRT treatment may be under-
reported when evaluated retrospectively. Finally, as
discussed previously, our data cannot establish whether a
7-mm expansion on the inguinal vessels is sufﬁcient for
the CTV because of the limited follow-up and the small
number of patients.
Conclusion
Our data add to the published literature on IMRT by
supporting its use in the postoperative setting. Deﬁnitive
treatment of vulvar cancer remains challenging, and the
LRC rates for patients treated without surgery were
unsatisfactory. We suggest several potential reﬁnements
to our deﬁnitive treatment technique based on our patterns
of recurrence. IMRT generally resulted in a low incidence
of severe side effects. Treatment of vulvar cancer with
IMRT is feasible and may be considered in future
patients. Additional studies are needed to evaluate the
efﬁcacy and beneﬁt of this treatment technique.
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